… ProQR Announces Presentations on Programs in Ophthalmology at … LEIDEN, the Netherlands, July 12, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … II Presentation at OIS Retina Daniel de Boer, CEO of ProQR, will give a presentation highlighting the company’s …
… ProQR Announces Presentations at the European Oligonucleotide … and CAMBRIDGE, Mass., Oct. 31, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … Peter Adamson, PhD, SVP Ophthalmology Science of ProQR Presentation : Thursday, November 8 at 14:15 - …
… ProQR Announces Annual Meeting of Shareholders to be Held May … (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through … be made available in the “Investors & Media” section of ProQR’s website ( www.proqr.com ) under “Financials and …
… ProQR Announces Fourth Quarter and Full Year 2021 Operating … & CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … in Q2,” said Daniel A. de Boer, Founder and CEO of ProQR. “Based on the previous data we have reported, we …
… ProQR Announces $30 Million Strategic Convertible Debt Financing Agreement with Pontifax Ventures Extends ProQR’s cash runway into 2023 ProQR can trigger conversion of … retinal diseases,” said Momi Karako, partner at Pontifax. “ProQR has expertise in antisense oligonucleotides, a …
Phase 2/3 pivotal Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data anticipated in H1 2022; Brighten pediatric trial of sepofarsen to begin in 2021; additional data from Phase 1/2 InSight extension study to be reported in
… ProQR Announces CTA Submission for Phase 1 Study of AX-0810 … first submitted Clinical Trial Application (CTA) advancing ProQR’s Axiomer™ ADAR-mediated RNA editing platform into … (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through …
… ProQR Reports Fourth Quarter and Full Year 2018 Operating and … & CAMBRIDGE, Mass., Feb. 27, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … Usher syndrome and adRP,” said Daniel A. de Boer, CEO of ProQR. “We are looking forward to an exciting 2019 where we …